Assessing the Impact of Electroacupuncture on Facial Thermal Characteristics of Major Depressive Disorder Patients Based on Infrared Thermal Imaging Technology
Major Depressive Disorder, Infrared Thermography
About this trial
This is an interventional diagnostic trial for Major Depressive Disorder
Eligibility Criteria
Inclusion Criteria:
Inclusion criteria for healthy subjects:
- Healthy subjects should provide a physical examination report within the last year, which could confirm they had not major systemic diseases, such as cardiovascular, respiratory, digestive, urinary, hematological, endocrine and neurological disease;
- 18 ≤ age ≤ 60 years, both gender;
- Subjects have clear consciousness and could communicate with others normally;
- Subjects could understand the full study protocol and written informed consent is provided by themselves. Note: Subjects who meet the above four items will be included.
Inclusion criteria for MDD patients:
- Meeting the above diagnostic criteria for MDD;
- PHQ-9 score of 5 to 14, HAMD score of 21 to 35, and a diagnosis of mild or moderate depression by a specialist; (3)18 ≤ age ≤ 60 years, both gender;
(4) Patients have clear consciousness and could communicate with others normally; (5) Patients could understand the full study protocol and written informed consent is provided by themselves; (6) Those who did not use other therapies other than the basic treatment and this experimental therapy. The basic treatment refers to basic antidepressant medications under the supervision of a specialist. The basic antidepressant medications are Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors, Norepinephrine-Dopamine Reuptake Inhibitors, Tricyclic antidepressants, Monoamine Oxidase Inhibitors. Note: Subjects who meet the above six items will be included.
Exclusion Criteria:
Exclusion criteria for healthy subjects:
- Subjects suffering from mental illness, severe depression, alcohol dependence or a history of drug abuse;
- Subjects in pregnancy, lactation or menstrual period;
- Subjects have a fever;
- Subjects have visible skin damage or scars in the face;
- Subjects participating in other trials. Note: Subjects who meet any of the above will be excluded.
Exclusion criteria for MDD patients:
- Patients with bipolar disorder;
- Patients with schizophrenia or other mental disorders;
- Patients with severe medical diseases, tumors or diseases of the central nervous system;
- Patients suffering from severe depressive episode with psychotic symptoms;
- Suicidal patients;
- Patients with seasonal depression;
- Patients with organic depression;
- Patients with alcohol or drug addicts;
- Patients using other therapies;
- Patients in pregnancy or lactation;
- Patients suffering from cognitive dysfunction, aphasia or other diseases that cannot cooperate with treatment;
- Patients with pacemakers;
- Patients who are not suitable for EA. Note: Subjects who meet any of the above will be excluded.
Sites / Locations
- Xiaoyu Li
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Healthy group
MDD electroacupuncture intervention group
MDD waiting-list group
Subjects in this group will not undergo acupuncture intervention. For participants in the healthy control group, the IRT examination of the measurement sites will last for 3 minutes, with one thermal image taken every 10s. In the Healthy group, there will be two visits, and the first visit will be considered as the screening stage (i.e., demographic data recording, medical history taking, physical examination report review and recording on the day of enrollment) and the second visit will be considered as the detection stage (i.e., the day of enrollment). At the second visit, the subjects received the Self-rating depression scale (SDS), HAMD, and then the infrared thermographic images to be acquired.
In this study, we used a waiting list control group. During the 4 weeks follow-up period, participants from the MDD waiting-list group had no contact with participants from the MDD EA intervention group and no access to the EA intervention. After the 4 weeks follow-up period, patients in the waiting list group received access to the EA intervention.